A prospective study of the hearing disorder in the patient receiving cisplatin

A prospective study of the hearing disorder in the patient receiving cisplatin - Cisplatin hearing disorder study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017989

Enrollment

100

Registered

2015-06-20

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

To give high dose cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Malignant tumor patient who will give more than 60 mg/m2 cisplatin 2) The patient who is evaluable in standard pure tone audiometry 3) Adult patient aged over 20 years 4) The patient that a document agreement by the free will after having received enough explanation on participating of this study

Exclusion criteria

Exclusion criteria: 1) The patient that periodical audiometry is impossible 2) Patient younger than 20 years 3) The patient who judged a study doctor to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Frequency of hearing disorder more than CTCAE Grade2	—

Secondary

Measure	Time frame
Toxicity, dose intensity of cisplatin, change of the mean hearing threshold level	—

Countries

Japan

Contacts

Public ContactHideaki Okada

Kobe minimally invasive cancer center Medical oncology

shumei_oka@joy.ocn.ne.jp078-304-4100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026